Practical combination therapy based on pathophysiology of type 2 diabetes
about
Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes.Pharmacotherapy of 'treatment resistant' type 2 diabetes.Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes.Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial.
P2860
Practical combination therapy based on pathophysiology of type 2 diabetes
description
2016 nî lūn-bûn
@nan
2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Practical combination therapy based on pathophysiology of type 2 diabetes
@ast
Practical combination therapy based on pathophysiology of type 2 diabetes
@en
Practical combination therapy based on pathophysiology of type 2 diabetes
@nl
type
label
Practical combination therapy based on pathophysiology of type 2 diabetes
@ast
Practical combination therapy based on pathophysiology of type 2 diabetes
@en
Practical combination therapy based on pathophysiology of type 2 diabetes
@nl
prefLabel
Practical combination therapy based on pathophysiology of type 2 diabetes
@ast
Practical combination therapy based on pathophysiology of type 2 diabetes
@en
Practical combination therapy based on pathophysiology of type 2 diabetes
@nl
P2860
P3181
P356
P1476
Practical combination therapy based on pathophysiology of type 2 diabetes
@en
P2093
Philip Levin
P2860
P304
P3181
P356
10.2147/DMSO.S109216
P407
P577
2016-10-31T00:00:00Z